Information Provided By:
Fly News Breaks for August 1, 2019
CRSP
Aug 1, 2019 | 07:45 EDT
Jefferies analyst Maury Raycroft started Crispr Therapeutics with a Buy rating and $64 price target. The company offers the best CRISPR/Cas9 development risk/reward profile, Raycroft tells investors in a research note. He believes that starting with sickle cell disease and beta-thalassemia will "de-risk" its broader pipeline. Crispr Therapeutics has "made strategically sound and differentiated decisions" that should play out in its favor for the longer term, contends the analyst.
News For CRSP From the Last 2 Days
CRSP
Apr 23, 2024 | 08:08 EDT
Meeting to be held in San Francisco on April 24 hosted by Mizuho.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.